Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. Dr. David J. Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target…
eTurboNews nkhani ndi za olembetsa okha. Kulembetsa ndi FREE.
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
ZOMWE MUNGACHITE PA NKHANIYI:
- Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target….
- Halia Therapeutics yapereka zambiri lero pa pulogalamu yake ya NLRP3 inhibitor pamsonkhano wamakono wapachaka wa 10 wa Neurodegenerative Drug Development Summit.
- Dr.
